TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36216430

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 160

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 160

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 160
Study: 32086272

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 32424376

Group type: EXPERIMENTAL
Intervention: Method A (presoaking in 1% sodium dodecyl sulfate followed by ultrasonication with 4 mol/L guanidine hydrochloride)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Method B (soaking in distilled water followed by ultrasonication with 4 mol/L guanidine hydrochloride)
Number of subjects: 40
Study: 36127097

Group type: EXPERIMENTAL
Intervention: Abdominal CT scanning following thoracic low-dose CT (LDCT) for lung cancer screening
Number of subjects: 4700

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 4700
Study: 32570654

Group type: EXPERIMENTAL
Intervention: e-Prescription systems
Number of subjects: 157
Study: 35019886

Group type: EXPERIMENTAL
Intervention: N‐ESAR foot prosthesis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Solid‐ankle cushioned‐heel prosthesis
Number of subjects: 20
Study: 34047299

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue (Glubran 2)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Absorbable tacks
Number of subjects: 106
Study: 35733183

Group type: EXPERIMENTAL
Intervention: Peer videorecording feedback training (PVF)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Traditional peer verbal feedback training (TVF)
Number of subjects: 127
Study: 34467834

Group type: EXPERIMENTAL
Intervention: Resveratrol 1000 mg daily for 3 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 35302628

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) summary with recommendations provided to oncologists prior to clinical encounter.
Number of subjects: 541
Study: 35921122

Group type: EXPERIMENTAL
Intervention: Nodal observation with ultrasonography
Number of subjects: 823
Study: 35421451

Group type: EXPERIMENTAL
Intervention: Aperiodic sensory stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Periodic sensory stimulation
Number of subjects: 0
Study: 35857241

Group type: EXPERIMENTAL
Intervention: Synbiotics (1 g containing both pre- and probiotics administered twice a day for 14 days)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (similar-looking to synbiotics)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 32928070

Group type: EXPERIMENTAL
Intervention: RFA plus compression (RF)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Compression alone (CR)
Number of subjects: 56
Study: 32619715

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using methylene blue mediated gallium aluminum arsenide laser at 635 nm, 6.5 J/cm2 for 10 seconds at 10 points, applied immediately after first wire and at days 3, 7, 14 of the first month, repeated for additional 2 months.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group without PDT intervention.
Number of subjects: 30
Study: 36126327

Group type: EXPERIMENTAL
Intervention: STRT+Leu (16 g of protein containing ∼3 g of leucine)
Number of subjects: 8

Group type: COMPARATOR
Intervention: STRT
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: STRT+Leu
Number of subjects: 8
Study: 32324711

Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS) protocols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modifications to typical ERAS protocols
Number of subjects: 0
Study: 33921737

Group type: EXPERIMENTAL
Intervention: Fitness training protocol consisting of three weekly sessions lasting 90 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Walking for 30-60 min three days a week without running or resistance training
Number of subjects: 40
Study: 32413530

Group type: EXPERIMENTAL
Intervention: Cranberry capsules
Number of subjects: 101

Group type: COMPARATOR
Intervention: Beetroot-containing placebo capsules
Number of subjects: 101
Study: 36353918

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with extra-virgin olive oil
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with nuts
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Energy-reduced Mediterranean diet with physical activity
Number of subjects: 463

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 463

Group type: COMPARATOR
Intervention: Ad libitum Mediterranean diet
Number of subjects: 463
Study: 33990958

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) of 60 mm Hg using norepinephrine (NE) infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mean arterial pressure (MAP) of 90 mm Hg using norepinephrine (NE) infusion
Number of subjects: 0
Study: 32830901

Group type: EXPERIMENTAL
Intervention: levodopa + donepezil (5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: levodopa
Number of subjects: 20
Study: 33893064

Group type: EXPERIMENTAL
Intervention: Twin Block appliance (RCT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Retrospectively selected cases (RSC) treated with Twin Block appliance
Number of subjects: 63
Study: 32534763

Group type: EXPERIMENTAL
Intervention: Probiotics, prebiotics, and psyllium product
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 10
Study: 36548296

Group type: EXPERIMENTAL
Intervention: MAP goal of 65 to 85 mmHg (L group)
Number of subjects: 116

Group type: COMPARATOR
Intervention: MAP goal of 86 to 100 mmHg (H group)
Number of subjects: 116
Study: 33485960

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1189
Study: 32393614

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 826

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 826
Study: 35063002

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine collaborative model (TCMCM) combined with usual adjuvant chemotherapy
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual adjuvant chemotherapy
Number of subjects: 260
Study: 32896933

Group type: EXPERIMENTAL
Intervention: Active tDCS and MBM regimen
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham tDCS and MBM regimen
Number of subjects: 19
Study: 35582947

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 6480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6480
Study: 33647220

Group type: EXPERIMENTAL
Intervention: Sentence length (2 to 7 words)
Number of subjects: 62
Study: 32335550

Group type: EXPERIMENTAL
Intervention: IVT + EVT
Number of subjects: 9117

Group type: COMPARATOR
Intervention: dEVT
Number of subjects: 9117
Study: 35038562

Group type: EXPERIMENTAL
Intervention: Social stress (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control condition (n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Stressed participants
Number of subjects: 80
Study: 33712252

Group type: EXPERIMENTAL
Intervention: Preoperative PECS block
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Postoperative PECS block
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 32969289

Group type: EXPERIMENTAL
Intervention: Health-related internet use (Y/N)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Health-related internet use
Number of subjects: 425
Study: 34448033

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 5095
Study: 35410405

Group type: EXPERIMENTAL
Intervention: TACE + RFA + Apatinib
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: TACE + Apatinib
Number of subjects: 175

Group type: COMPARATOR
Intervention: TACE Alone
Number of subjects: 175
Study: 32199246

Group type: EXPERIMENTAL
Intervention: Cognitive load induced by the verb generation task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control baseline condition (no verb generation task)
Number of subjects: 0
Study: 36006698

Group type: EXPERIMENTAL
Intervention: MoVo‐LISA intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (treatment‐as‐usual)
Number of subjects: 202
Study: 34580282

Group type: EXPERIMENTAL
Intervention: Active tDCS (20 min, 2 mA) before every Lokomat session (30 min, 3 times a week for 12 weeks or 5 times a week for 6 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham tDCS (20 min, 2 mA) before every Lokomat session (30 min, 3 times a week for 12 weeks or 5 times a week for 6 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 43
Study: 33308548

Group type: EXPERIMENTAL
Intervention: Service-learning experience
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Research training
Number of subjects: 35
Study: 34062937

Group type: EXPERIMENTAL
Intervention: Oat β-Glucan (1 g OBG, n = 104)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Oat β-Glucan (1 g OBG)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control (n = 103)
Number of subjects: 207
Study: 32077300

Group type: EXPERIMENTAL
Intervention: Wellness committee implementation index (WC index)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Wellness committee (WC)
Number of subjects: 23
Study: 35560850

Group type: EXPERIMENTAL
Intervention: 10% kcal carbohydrate diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30% kcal carbohydrate diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All dietary treatments (10%, 15%, 20%, 25%, 30% kcal carbohydrate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All dietary treatments
Number of subjects: 12
Study: 34180414

Group type: EXPERIMENTAL
Intervention: PLIÉ intervention (twice weekly classes for 12 weeks)
Number of subjects: 18
Study: 32298656

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 35733098

Group type: EXPERIMENTAL
Intervention: Conventional speech therapy + functional electrotherapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional speech therapy
Number of subjects: 33
Study: 32013412

Group type: EXPERIMENTAL
Intervention: MnIV4O4 complex
Number of subjects: 0

Group type: COMPARATOR
Intervention: MnIIIMnIV3O4 cuboidal complex
Number of subjects: 0
Study: 35615728

Group type: EXPERIMENTAL
Intervention: Pregabalin treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 36341216

Group type: COMPARATOR
Intervention: 25, 75, 150, 300, 450, or 600 mg tafolecimab subcutaneously, 75 or 450 mg intravenously
Number of subjects: 118

Group type: COMPARATOR
Intervention: 75 or 140 mg tafolecimab every 2 weeks, 300 or 420 mg every 4 weeks, or 450 or 600 mg every 6 weeks subcutaneously
Number of subjects: 118

Group type: COMPARATOR
Intervention: Single dose of tafolecimab
Number of subjects: 118
Study: 35954581

Group type: EXPERIMENTAL
Intervention: Fixed dosing intervals
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Flexible dosing intervals
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 193
Study: 32348815

Group type: EXPERIMENTAL
Intervention: Informational approach (knowledge group)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Affect-based approach (affect group)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 448
Study: 34598852

Group type: EXPERIMENTAL
Intervention: SUMMIT mattress
Number of subjects: 31

Group type: COMPARATOR
Intervention: NIMBUS 3 mattress
Number of subjects: 31
Study: 33039478

Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy (AIT) with allergoids to birch and/or grass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 0
Study: 32133662

Group type: EXPERIMENTAL
Intervention: Surgical repair of medial condylar fracture
Number of subjects: 43
Study: 33682648

Group type: EXPERIMENTAL
Intervention: Continuation with sertraline (50 mg/day)
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: Continuation with sertraline (100 mg/day)
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: Optimized treatment (individualized treatment rule)
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Switching to mirtazapine
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Combining mirtazapine with sertraline
Number of subjects: 1549
Study: 34998427

Group type: EXPERIMENTAL
Intervention: Fluralaner (oral administration at the approved dose on day 0)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not treated)
Number of subjects: 12
Study: 33956987

Group type: EXPERIMENTAL
Intervention: Ventral posterior medial (VPM) stimulation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Centromedian (CM) stimulation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: VPM-DBS in combination with lateral CM stimulation
Number of subjects: 1
Study: 35419985

Group type: EXPERIMENTAL
Intervention: Cuttlebone toothpaste (Dr. D‐Tart)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Crest toothpaste (control)
Number of subjects: 81
Study: 34289755

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg at steady-state with levothyroxine (600 μg single-dose)
Number of subjects: 45

Group type: COMPARATOR
Intervention: SNAC 300 mg with levothyroxine (600 μg single-dose)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oral semaglutide 14 mg at steady-state with five placebo tablets
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oral semaglutide 14 mg at steady-state alone
Number of subjects: 45
Study: 32723352

Group type: EXPERIMENTAL
Intervention: Zinc sulfate mucoadhesive tablet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 35099205

Group type: EXPERIMENTAL
Intervention: eBridge (personalized feedback with option of online counseling)
Number of subjects: 3363

Group type: COMPARATOR
Intervention: Control (personalized feedback)
Number of subjects: 3363
Study: 33475701

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 2800 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 7000 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Bamlanivimab and Etesevimab (2800 mg each)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 33886909

Group type: EXPERIMENTAL
Intervention: Telephone monitoring for symptoms, quality of life, distress, admissions to the emergency center, and satisfaction
Number of subjects: 81

Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 81
Study: 35597385

Group type: EXPERIMENTAL
Intervention: Balloon-Expandable Valve (BEV) SAPIEN (3/ULTRA, Edwards Lifesciences)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Self-Expanding Valve (SEV) Evolut (R/PRO/PRO+, Medtronic)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Invasive valve hemodynamic evaluation (both groups)
Number of subjects: 102
Study: 33235041

Group type: EXPERIMENTAL
Intervention: Standardized pain management education
Number of subjects: 267

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 267
Study: 32175948

Group type: EXPERIMENTAL
Intervention: McGrath video laryngoscope
Number of subjects: 130

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscopy
Number of subjects: 130
Study: 32968915

Group type: EXPERIMENTAL
Intervention: e‐TEP
Number of subjects: 92

Group type: COMPARATOR
Intervention: IPOM Plus
Number of subjects: 92
Study: 32977831

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 33830234

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham needling
Number of subjects: 50
Study: 32164563

Group type: EXPERIMENTAL
Intervention: HDL-c increase
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Total Cholesterol (TC) increase at 20 weeks gestation
Number of subjects: 573

Group type: COMPARATOR
Intervention: Low HDL-c at enrolment
Number of subjects: 573

Group type: COMPARATOR
Intervention: Low HDL-c at 20 weeks gestation
Number of subjects: 573

Group type: COMPARATOR
Intervention: High LDL-c at 30 weeks gestation
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Total Cholesterol (TC) increase at 30 weeks gestation
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: LDL-c increase at 30 weeks gestation
Number of subjects: 573
Study: 33836708

Group type: EXPERIMENTAL
Intervention: Individually targeted human milk fortification with protein and fat modulars based on daily point‐of‐care milk analysis.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard fortification (control group).
Number of subjects: 130
Study: 33221776

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block
Number of subjects: 74

Group type: COMPARATOR
Intervention: Wound infiltration (WI)
Number of subjects: 74
Study: 35380713

Group type: EXPERIMENTAL
Intervention: Cetuximab 500 mg/m2, bevacizumab 5 mg/kg, and irinotecan 180 mg/m2 (CBI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cetuximab and irinotecan with placebo (CI)
Number of subjects: 36
Study: 32713051

Group type: EXPERIMENTAL
Intervention: Removal of sugar-sweetened beverages (SSBs) from sale in hospitals
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Support for SSB removal among staff and visitors
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Perception of health improvement due to SSB removal
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Awareness of SSB removal among staff vs visitors
Number of subjects: 2394
Study: 32772304

Group type: EXPERIMENTAL
Intervention: Pharmacists providing clinical pharmacy services
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Pharmacists reviewing medication orders
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Pharmacists monitoring patients' response to therapy and adverse drug effects
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Collaboration with pharmacists in developing treatment plans
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Improving doctor-pharmacist collaborations through trust and dialogue
Number of subjects: 119

Group type: COMPARATOR
Intervention: Demographic characteristics related to doubt in pharmacist clinical competence
Number of subjects: 119
Study: 34825307

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (5 years treatment)
Number of subjects: 1735

Group type: COMPARATOR
Intervention: Placebo (CCTG MA.17R trial)
Number of subjects: 1735
Study: 32471770

Group type: EXPERIMENTAL
Intervention: Diabetes education and SMS reminders for six months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101
Study: 32693615

Group type: EXPERIMENTAL
Intervention: N-butyl-cyanoacrylate + Metacryloxysulfolane
Number of subjects: 142

Group type: COMPARATOR
Intervention: Suture Alone
Number of subjects: 142
Study: 33234638

Group type: EXPERIMENTAL
Intervention: Choosing Health digital intervention
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group (non-tailored weight loss advice via e-book and generic emails)
Number of subjects: 285
Study: 34187067

Group type: EXPERIMENTAL
Intervention: Robotic arm-assisted TKA (RA-TKA)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Manual TKA
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Both RA-TKA and Manual TKA
Number of subjects: 340
Study: 34798826

Group type: EXPERIMENTAL
Intervention: Pharmacist-led, deprescribing-focused medication review, followed by an individualised treatment modification plan.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 62
Study: 32721212

Group type: EXPERIMENTAL
Intervention: 174 Hz unweighted tuning fork (TF) used by practitioners to comb the same four sites per subject
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Statistical analysis using a Monte Carlo approach
Number of subjects: 10
Study: 35974369

Group type: EXPERIMENTAL
Intervention: Exp I: active and passive activity training (APAT) + NMES treatment on the gastrocnemius and tibialis anterior muscle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exp II: APAT + NMES treatment on gastrocnemius alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ctl: APAT alone
Number of subjects: 0
Study: 33958128

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support to reach energy, protein, and micronutrient goals
Number of subjects: 645

Group type: COMPARATOR
Intervention: Standard hospital food
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 645
Study: 32804970

Group type: EXPERIMENTAL
Intervention: ART (specific regimens not detailed)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: NRTIs
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: NNRTIs
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: PIs
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: M184V mutation
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: K65R mutation
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: TAMs
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: K103N mutation
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Other NNRTI mutations
Number of subjects: 273
Study: 36137090

Group type: EXPERIMENTAL
Intervention: Training (interactive computerised presentations)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Active control procedure
Number of subjects: 10
Study: 32220944

Group type: EXPERIMENTAL
Intervention: Early specialised palliative care (SPC) interventions
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Pain interventions
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Impaired physical function interventions
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: No documented interventions
Number of subjects: 145
Study: 32460565

Group type: EXPERIMENTAL
Intervention: Calendula ointment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 32698121

Group type: EXPERIMENTAL
Intervention: Higher protein diet (2.50 g·kg‐1·day‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Moderate protein diet (1.25 g·kg‐1·day‐1)
Number of subjects: 18